Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + iodine I 131 tositumomab
- Development stage
- Discontinued
- Lead developer
- Corixa
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Rituximab + iodine I 131 tositumomab is a combination regimen used in the treatment of certain types of non-Hodgkin's lymphoma, particularly CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma. Rituximab is a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes and works by depleting both normal and malignant B cells. Iodine I 131 tositumomab (Bexxar) consists of a murine monoclonal antibody (tositumomab) directed against CD20 that is covalently linked to radioactive iodine (Iodine-131). This radioimmunotherapeutic agent delivers targeted radiation to B cells expressing CD20 through its radiolabeled component while also engaging immune-mediated cytotoxicity via the antibody. The combination is primarily indicated for patients whose disease has progressed during or after rituximab therapy[1][2][3][5].
- Other names
- tositumomab and iodine I 131 tositumomab
02
Targets
Beyond the preview
Go deeper on rituximab + iodine I 131 tositumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + iodine I 131 tositumomab.